（一）审议通过《关于<2024 年半年度报告>及其摘要的议案》 经审核，监事会认为：董事会编制和审核公司 2024 年半年度报告的程序符 合法律、行政法规和中国证监会的规定，半年报内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 证券代码：301101 证券简称：明月镜片 公告编号：2024-026 明月镜片股份有限公司 第二届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届监事会第十四次会议于 2024 年 8 月 20 日在公司会议室以现场表决方式召开。本次会议通知于 2024 年 8 月 9 日以专人送达、电话、微信等形式通知了全体监事。本次会议由监事会主 席朱海峰先生召集并主持，应出席公司会议的监事 3 人，实际出席公司会议的监 事 3 人。会议召开符合《中华人民共和国公司法》、《公司章程》等规定，会议合 法有效。 二、监事会会议审议情况 经与会监事充分讨论，本次会议审议通过议案如下： 经审核，监事会认为：公司本次部 ...

| 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2、督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 | | | | 是 | | 募集资金管理制度、内控制度、内部审计制 | | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月查询一次 | | （2）公司募集资金项目进展是否与信息披 | 是 | | 露文件一致 | | | 4、公司治理督导情况 | | | （1）列席公司股东大会次数 | 0，均事前或事后审阅会议议案 | | （2）列席公司董事会次数 | 0，均事前或事后审阅会议议案 | 1 | （3）列席公司监事会次数 | 0，均事前或事后审阅会议议案 | | --- | --- | | 5、现场检查情况 | | | （1）现场检查次数 | ...

明月镜片股份有限公司 舆情管理制度 第一章 总 则 第一条 为提高明月镜片股份有限公司（以下简称"公司"）应对各类舆情 的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股价、 公司商业信誉及正常生产经营活动造成的影响，切实保护投资者和公司的合法权 益，根据《深圳证券交易所创业板股票上市规则》等相关法律法规的规定和《明 月镜片股份有限公司章程》（以下简称"《公司章程》"），结合公司实际情况， 特制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第七条 舆情信息采集范围应涵盖公司及控股子公司官网、微信公众号、抖 音官方账号、网络媒体、电子报、微信、微博、博客、互动易问答、论坛、贴吧、 股吧等各类型信息载体。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一 组织、快速反应、协同 ...

证券代码：301101 证券简称：明月镜片 公告编号：2024-025 明月镜片股份有限公司 第二届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 明月镜片股份有限公司（以下简称"公司"）第二届董事会第十四次会议于 2024 年 8 月 20 日在公司会议室以现场结合通讯的表决方式召开。本次会议通知于 2024 年 8 月 9 日以专人送达、电话、微信的方式通知了全体董事。本次会议由董事长谢 公晚先生主持，应出席会议董事 7 人，实际参加会议董事 7 人，公司监事、高级管 理人员列席会议。会议召开符合《中华人民共和国公司法》、《公司章程》等规定， 会议合法有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<2024 年半年度报告>及其摘要的议案》； 公司董事会审计委员会已审议通过该议案。 表决结果：7 票同意；0 票反对；0 票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2024 年 半年度报告》及《2024 年半年度 ...

东方证券承销保荐有限公司 关于明月镜片股份有限公司 部分募投项目延期的核查意见 东方证券承销保荐股份有限公司（以下简称"东方证券"或"保荐机构"）作为 明月镜片股份有限公司（以下简称"明月镜片"或"公司"）首次公开发行股票并在 创业板上市之保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》等有关规定，对明月镜片部分募投项目延期的事项进行了 核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意明月镜片 股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕3473 号）同意 注册，明月镜片获准首次公开发行人民币普通股（A 股）股票 3,358.54 万股，每 股面值 1 元，每股发行价格为人民币 26.91 元，募集资金总额为人民币 903,783,114.00 元，扣除各 类发行费用后实际募集资金净额为人民币 792,923,877.64 元。上述募集资金到位情况经立信会 ...

证券代码：301101 证券简称：明月镜片 公告编号：2024-024 明月镜片股份有限公司 关于股价异常波动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 明月镜片股份有限公司（以下简称"公司"或"本公司"）于 2024 年 8 月 13 日、8 月 14 日连续 2 个交易日收盘价格涨幅偏离值累计达到 30%以上。根据深圳 证券交易所的有关规定，属于股票交易异常波动的情形。 二、公司关注并核实相关情况 针对公司股票异常波动情况，公司董事会通过现场、电话及通信等方式，对公 司控股股东、实际控制人、公司全体董事、监事及高级管理人员就相关问题进行了 核实，现就相关情况说明如下： 1、截至本公告日，公司前期披露的信息不存在需要更正、补充之处； 2、公司及控股股东、实际控制人不存在应披露而未披露的重大事项，也不存 在处于筹划阶段的重大事项； 1、经自查，公司不存在违反信息公平披露的情形。 2、公司于 2024 年 7 月 22 日披露了《2024 年半年度业绩预告》（公告编号： 2024-023），具体内容详见公司披露于巨潮资讯网 ...

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company has demonstrated stable revenue and profit performance, with a focus on product structure upgrades and a "1+3" big product strategy, leading to steady growth in a challenging consumption environment [2][3] - The partnership with Leica is set to deepen, with plans for a joint launch event in the second half of 2024, marking a significant step in the high-end lens market in China [3] - Profitability is expected to rise steadily, with projected net profits of 180 million, 218 million, and 263 million yuan for 2024, 2025, and 2026 respectively, corresponding to P/E ratios of 23.7X, 19.6X, and 16.2X [3] Financial Performance Summary - Revenue for 2024 is projected to reach 833 million yuan, with a year-over-year growth rate of 11.3% [4] - The net profit for 2024 is estimated at 180 million yuan, reflecting a year-over-year growth of 14.3% [4] - The company’s EPS is expected to increase from 0.78 yuan in 2023 to 0.89 yuan in 2024 [4] - The return on equity (ROE) is projected to improve from 10.8% in 2023 to 11.3% in 2024 [4] Product Strategy and Market Position - The company is advancing its "1+3" big product strategy, with significant growth in key product lines such as the PMC Ultra Bright series and blue light blocking lenses, which saw revenue increases of 77%, 33%, and 22% respectively in Q1 2024 [2][3] - The share of these key products in total revenue has risen to 54%, indicating a successful product matrix optimization [2]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price indicating an expected return of over 20% within the next six months [21]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of between 41.34 million and 50.62 million yuan in Q2 2024, reflecting a year-on-year change of -8.3% to +12.3% [1]. - The company has optimized its product structure, focusing on star products and the growing category of defocus lenses, which are projected to continue strong growth [2][4]. - The company has implemented a customer tiering strategy, enhancing its channel competitiveness and focusing on mid-to-large clients, which is expected to improve profitability steadily [3]. Financial Performance Summary - The company's revenue is projected to grow from 623.07 million yuan in 2022 to 1,202.54 million yuan in 2026, with a compound annual growth rate (CAGR) of approximately 15.47% [6]. - The net profit attributable to shareholders is expected to increase from 136.19 million yuan in 2022 to 285.72 million yuan in 2026, with a CAGR of about 20.15% [6]. - The company's earnings per share (EPS) is forecasted to rise from 0.68 yuan in 2022 to 1.42 yuan in 2026 [6]. Product and Market Strategy - The company has a comprehensive product line in traditional lenses, with three star products showing robust growth despite external pressures, with year-on-year revenue increases of 77%, 33%, and 22% for different product lines in Q1 2024 [2]. - The defocus lens segment is experiencing rapid growth, with sales expected to continue increasing, supported by a wide retail channel and effective marketing strategies [2][5]. - The company has established a strong market position in the defocus lens market, capturing 62% of the market share, while maintaining an upward trend in product pricing [5].

Investment Rating - The report maintains a rating of "Accumulate" for the company with a target price of 23.2 CNY [9] Core Viewpoints - The company is expected to achieve a net profit attributable to shareholders of 83.55 million to 92.83 million CNY in 2024, representing a year-on-year growth of 4.3% to 15.9% [2] - The company's product structure is continuously optimized, with a focus on the "1+3+N" product layout, leading to an expected steady increase in profitability [4] - The company has a significant market position in the defocus lens segment, with sales expected to continue growing despite industry price competition [3][6] Financial Performance - The company’s revenue is projected to grow from 623.07 million CNY in 2022 to 1,202.54 million CNY by 2026, with a compound annual growth rate (CAGR) of approximately 15.47% [15] - The net profit attributable to the parent company is forecasted to increase from 136.19 million CNY in 2022 to 285.72 million CNY in 2026, reflecting a growth rate of 20.15% [15] - The company’s EBITDA is expected to rise from 220.25 million CNY in 2022 to 425.64 million CNY in 2026 [15] Product and Market Strategy - The company has successfully maintained a high average selling price for its products, transitioning from first-generation to second-generation products while preparing for future market changes [3] - The defocus lens segment is experiencing rapid growth, with sales expected to increase by 50% year-on-year in Q1 2024 [6] - The company is focusing on large and medium-sized clients, enhancing its channel competitiveness through targeted marketing and service innovations [7][15] Future Outlook - The company anticipates continued growth in its star products and defocus lenses, with net profit projections for 2024, 2025, and 2026 at 195.44 million CNY, 237.80 million CNY, and 285.72 million CNY respectively [4][15] - The report highlights the company's ability to adapt its marketing strategies in response to external pressures, ensuring a broad coverage of retail channels [6][14]

Financial Performance - The net profit attributable to shareholders is expected to be between 83.55 million and 92.83 million CNY, representing a year-on-year growth of 4.28% to 15.86% compared to 80.12 million CNY in the same period last year [3] - The net profit after deducting non-recurring gains and losses is projected to be between 71.96 million and 77.84 million CNY, with a year-on-year growth of 2.09% to 10.44% compared to 70.48 million CNY last year [3] Business Strategy - The company attributes the performance improvement to a focus on product strategy, with growth in star products and the "Easy Control" series for juvenile myopia prevention [7] Financial Reporting - The financial data in this earnings forecast is preliminary and has not been audited by a registered accounting firm [7] - The specific financial data will be detailed in the company's 2024 semi-annual report [7]